Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 954,659
  • Shares Outstanding, K 154,726
  • Annual Sales, $ 58,440 K
  • Annual Income, $ -80,740 K
  • 60-Month Beta 1.47
  • Price/Sales 15.54
  • Price/Cash Flow N/A
  • Price/Book 6.33
Trade OCUL with:

Options Overview Details

View History
  • Implied Volatility 85.49% ( -1.38%)
  • Historical Volatility 112.45%
  • IV Percentile 23%
  • IV Rank 15.02%
  • IV High 359.40% on 11/13/23
  • IV Low 37.09% on 10/12/23
  • Put/Call Vol Ratio 1.38
  • Today's Volume 1,929
  • Volume Avg (30-Day) 1,149
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 24,583
  • Open Int (30-Day) 28,485

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.20
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +41.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.06 +51.97%
on 04/26/24
8.94 -30.98%
on 04/04/24
-2.28 (-26.98%)
since 04/03/24
3-Month
4.06 +51.97%
on 04/26/24
11.31 -45.45%
on 03/06/24
+0.99 (+19.11%)
since 02/02/24
52-Week
2.00 +209.27%
on 11/10/23
11.31 -45.45%
on 03/06/24
-0.02 (-0.32%)
since 05/03/23

Most Recent Stories

More News
2 Small-Cap Growth Stocks With Room To Run

These two small-cap growth stocks could be ready to run.

REGN : 957.00 (+2.07%)
RHHBY : 29.8300 (+1.95%)
ACHR : 3.96 (-1.25%)
OCUL : 6.17 (+5.11%)
Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix: Q4 Earnings Snapshot

OCUL : 6.17 (+5.11%)
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.

BIIB : 217.51 (+1.87%)
XBI : 89.98 (+1.86%)
XLK : 202.55 (+2.79%)
OCUL : 6.17 (+5.11%)
LRMR : 7.76 (+2.04%)
Ocular Therapeutix: Q3 Earnings Snapshot

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL : 6.17 (+5.11%)
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

/PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical,...

OCUL : 6.17 (+5.11%)
Ocular Therapeutix: Q2 Earnings Snapshot

Ocular Therapeutix: Q2 Earnings Snapshot

OCUL : 6.17 (+5.11%)
Stocks Set to Open Higher as Investors Await Fed Meeting, Inflation Data

June S&P 500 futures (ESM23) are up +0.23%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.46% this morning as market participants looked ahead to the latest U.S. inflation data and the Federal Reserve’s...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
TSLA : 181.19 (+0.66%)
GM : 44.86 (+0.43%)
ADBE : 486.18 (+2.02%)
NFLX : 579.34 (+2.51%)
TGT : 158.04 (-0.05%)
CMA : 53.07 (+2.31%)
ZION : 43.62 (+2.11%)
ADS.D.DX : 224.900 (+0.47%)
NOVN.Z.IX : 87.910 (-0.99%)
GF.Z.IX : 65.650 (+2.98%)
AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients

/PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical,...

OCUL : 6.17 (+5.11%)
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 6.17 (+5.11%)
XERS : 1.8900 (+1.61%)
Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix: Q1 Earnings Snapshot

OCUL : 6.17 (+5.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 6.73
2nd Resistance Point 6.56
1st Resistance Point 6.37
Last Price 6.17
1st Support Level 6.00
2nd Support Level 5.83
3rd Support Level 5.64

See More

52-Week High 11.31
Fibonacci 61.8% 7.75
Fibonacci 50% 6.65
Last Price 6.17
Fibonacci 38.2% 5.55
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar